BEIJING (Reuters) - Chinese regulators have approved Novartis’ Mayzent to treat relapsing multiple sclerosis in adults, the Swiss drug maker said in a statement on Saturday.
Other drugs approved by China’s National Medical Products Administration to treat MS include Novartis’ Gilenya, Bayer’s Betaferon and Sanofi’s Aubagio. China has an estimated 30,000 patients with MS.
Reporting by Roxanne Liu and Kevin Yao in Beijing; Editing by Edwina Gibbs
Our Standards: The Thomson Reuters Trust Principles.